E-Mail
Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology s 70th Annual Scientific Session. The researchers, while acknowledging the results were not statistically significant, said they were encouraged by the lower numbers of organ failure and deaths observed in patients treated with dapagliflozin and by favorable safety data.
COVID-19 can lead to multi-organ failure, especially in patients at high risk for severe illness and complications. The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial was the first phase III randomized, controlled clinical trial that was initiated to determine whether dapagliflozin could reduce cardiovascular, kidney and respiratory complications
Medical Societies Support Safety and Benefits of Ultrasound Contrast Agents
May 11, 2021 The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE) have joined the International Contrast Ultrasound Society (ICUS) in recognizing the relatively low risk and important clinical benefits of ultrasound contrast agents (UCAs), which are used routinely around the world to help detect heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adults and children.
All three medical societies issued statements reacting to a recent communication from the Food and Drug Administration “stakeholder engagement staff” citing 13 suspected adverse reactions to polyethylene glycol (PEG), an inactive ingredient in two UCAs, without mentioning that reactions to UCAs are extremely rare and the 13 cases at issue were drawn from historical da
Second Generation Robotic PCI System Performs Well Across Spectrum of Lesion Complexity
Multicenter PRECISION GRX Study showed the Siemens Corpath GRX is safe and effective in variety of real-world lesions
The Corindus CorPath robotic cath lab navigation system allows operators to sit and control the procedure from behind a lead-lined booth, so they do not have to wear heavy aprons during the procedures.
May 5, 2021 A late-breaking study of the Siemens Healthineers Corindus Corpath GRX second-generation cath lab robotic system had high rates of clinical and technical success across the spectrum of lesion complexity. The multicenter PRECISION GRX Study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 meeting.
Regulatory News:
Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK). This non-interventional clinical study aims to better understand renin-angiotensin-aldosterone system inhibitors (RAASi) treatment decisions in clinical practice, potential barriers to achieving optimal guideline-directed care in HF patients with or at high risk for HK, and to assess how Veltassa ® may be used in the management of this patient population.
âOne of the most pressing issues in management of chronic heart failure is that therapies that have proven to reduce the risk of death and hospitalizations, and are thus strongly recommended by the guidelines, are not optimally used in clinical practice. This is certainly the case with RAASi, which are under-used in many patients, especially those with or at high risk of hyperkalemia,â said Dr. Mikhail Kosiborod